Covenant Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Covenant Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.85M	Sell	11,782 -299	-2%	-$133K	0.98%	34
2026 Q1	$5.39M	Buy	12,081 +192	+2%	+$89.5K	0.81%	40
2025 Q4	$5.39M	Sell	11,889 -215	-2%	-$92.7K	0.64%	38
2025 Q3	$4.74M	Sell	12,104 -51	-0.4%	-$21.3K	0.54%	45
2025 Q2	$5.41M	Sell	12,155 -387	-3%	-$178K	0.8%	33
2025 Q1	$6.08M	Sell	12,542 -85	-0.7%	-$39.6K	1.34%	21
2024 Q4	$5.08M	Sell	12,627 -137	-1%	-$63.5K	0.78%	34
2024 Q3	$5.94M	Buy	12,764 +118	+0.9%	+$56.7K	0.93%	32
2024 Q2	$5.93M	Buy	12,646 +553	+5%	+$240K	0.94%	28
2024 Q1	$5.05M	Buy	12,093 +799	+7%	+$338K	0.83%	33
2023 Q4	$4.6M	Buy	11,294 +252	+2%	+$93.1K	0.83%	31
2023 Q3	$3.84M	Sell	11,042 -9	-0.1%	-$3.15K	1.01%	28
2023 Q2	$3.89M	Sell	11,051 -19	-0.2%	-$6.4K	0.99%	34
2023 Q1	$3.49M	Buy	11,070 +403	+4%	+$121K	0.83%	39
2022 Q4	$3.08M	Buy	10,667 +79	+0.7%	+$24.1K	0.74%	46
2022 Q3	$3.07M	Sell	10,588 -92	-0.9%	-$26.5K	0.87%	34
2022 Q2	$3.01M	Buy	+10,680	New	+$2.86M	0.96%	34
2021 Q2	–	Sell	-1,000	Closed	-$215K	–	151
2021 Q1	$215K	Sell	1,000 -17,074	-94%	-$3.75M	0.07%	139
2020 Q4	$4.27M	Buy	18,074 +306	+2%	+$70.2K	1.41%	17
2020 Q3	$4.83M	Sell	17,768 -173	-1%	-$47.7K	1.55%	12
2020 Q2	$5.21M	Sell	17,941 -326	-2%	-$88.4K	1.15%	16
2020 Q1	$4.35M	Sell	18,267 -81	-0.4%	-$18.6K	1.31%	14
2019 Q4	$4.02M	Sell	18,348 -520	-3%	-$105K	1.76%	10
2019 Q3	$3.2M	Buy	18,868 +446	+2%	+$78.9K	1.61%	10
2019 Q2	$3.38M	Buy	18,422 +307	+2%	+$53.7K	1.75%	12
2019 Q1	$3.33M	Buy	18,115 +66	+0.4%	+$12.2K	1.75%	12
2018 Q4	$3.48M	Hold	18,049	–	–	1.75%	11
2018 Q3	$3.48M	Sell	18,049 -486	-3%	-$86.5K	1.75%	11
2018 Q2	$3.15M	Buy	18,535 +1,449	+8%	+$225K	1.7%	13
2018 Q1	$2.79M	Buy	+17,086	New	+$2.79M	1.61%	13

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Covenant Asset Management's VRTX Position: Q2 2026 in Review

Covenant Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 2.5% in Q2 2026, selling an estimated $133K and leaving 11,782 shares worth $5.85M. The position accounts for 0.98% of the portfolio, ranked #34.

Covenant Asset Management first reported a position in VRTX in Q1 2018 and has held it in 30 quarters since. The position peaked at $6.08M in Q1 2025. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Covenant Asset Management held 11,782 shares of Vertex Pharmaceuticals worth $5.85M as of Q2 2026.
Covenant Asset Management sold 299 Vertex Pharmaceuticals shares in Q2 2026, an estimated $133K.
Vertex Pharmaceuticals made up 0.98% of Covenant Asset Management's portfolio in Q2 2026, its #34 holding.
Covenant Asset Management first reported a position in Vertex Pharmaceuticals in Q1 2018 and has held it in 30 quarters since.
Covenant Asset Management's Vertex Pharmaceuticals position peaked at $6.08M in Q1 2025.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Covenant Asset Management's 13F filing for Q2 2026, filed 20 Jul 2026.